Home > Gastroenterology > Thiopurine alone maintains remission in more than half of UC patients

Thiopurine alone maintains remission in more than half of UC patients

Journal
Gut
Reuters Health - 14/10/2020 - Thiopurine monotherapy is an effective, durable treatment for ulcerative colitis (UC), but it is less likely to be effective in patients with Crohn's disease (CD), according to a study of nearly 12,000 patients. About 53% of UC patients were able to maintain long-term remission on azathioprine (AZA) or 6-mercaptopurine (6MP) only, compared to a third of CD patients, Dr. Miles Parkes of Cambridge University Hospital in the U.K. and colleagues report in Gut. Median remission time with successful treatment was 16 years in CD patients and 17 years for UC patients. "The strength of our study is the size of the data set and the length of follow-up," Dr. Parkes told Reuters Health by phone. Biologics have been promoted heavily for treating IBD, with some opinion leaders saying thiopurines no longer have a role in IBD treatment, he noted. But with lifelong illnesses such as UC and CD, treatment durability is important, and many of the ne...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on